Business Wire

TORG - World’s First Sustainability Driven Cryptocurrency Goes Live on Global Exchanges!

Share

Cryptocurrencies seem to be the flavour of the season as increasingly more people around the world are embracing them; sometimes even abandoning their traditional avenues like Equity, Gold, etc. Though the concept of crypto (as they are informally called) investment seems novel, the first cryptocurrency came into the market more than a decade back. The reliable supply, decentralised control, swift success, and exorbitant returns given by cryptocurrencies have now allayed all fears of them being a ‘fad’ or even a ‘sham’. Today, you have many different options of cryptocurrencies trading on different real-time online platforms.

Though, as the cryptocurrencies do not have any underlying asset to base your buying or selling decision upon (for example – Google shares move on the performance of the Google companies), all the cryptocurrencies on the face look similar. But, one cryptocurrency, recently launched, is destined to change all that, and is already making waves around the world as people are lapping it up in droves.

TORG is the world’s first sustainability driven, completely decentralized, and utility-focused cryptocurrency, aimed at global human development. If it sounds confusing, it’s because it’s such a new concept. As the world’s first utilimeme, it combines the power of meme-driven popularity with the sustainability that comes with a focus on global utility.

Launched recently on 20th July 2021, TORG has already reached the maximum supply of 777 billion and its current circulating supply is 100%. TORG is secured as an ERC-20 token on the Ethereum blockchain. It is not open to pausing, minting, and mining. Being extremely secure and stable, TORG’s smart contract is audited by the best in the industry blockchain security and infrastructure leader Certik.

TORG started trading from 20th July 2021 on world’s leading Global Exchanges, namely Uniswap, BitMart, CoinTiger, ProBit, CoinsBit Global, CoinsBit India, WhiteBit, HotBit.io, LA Token, IndoEx International, Bilaxy, etc. It is expanding its reach rapidly and is expected to be available on many trading platforms, big & small, shortly. Since the launch, different pairs of TORG have been added by the centralized exchanges,including TORG/USDT, TORG/BTC, and TORG/ETH.

TORG – It is different, but is it better?

What makes TORG better than other cryptocurrencies is the same thing that makes the world a better place to live in, i.e. focus on sustainability. TORG is not just any regular cryptocurrency. It is the world’s first cryptocurrency that has sustainability & utility as its underlying core assets. It aims to increase commercial & business activities, generate growth & employment opportunities for the world’s youth, develop eco-friendly infrastructure around the world, push the population to adopt green initiatives, and alleviate the economic constraints facing the world’s marginalized demographic sections.

About TORG

TORG Foundation is the force behind this intuitive & innovative cryptocurrency that aims to disrupt the crypto market forever. With the mission & vision of helping the society keep its carbon footprint to the minimum while increasing the economic activities both in developing & developed countries for the holistic development of mankind, the foundation keeps the interests of humanity and mankind at the core of all its decisions.

To maintain the full transparency of transactions, TORG is completely decentralised, and the foundation does not & cannot decide or predict its price movements.

It’s #TORGTime.

For more information and updates, visit www.torg.to or follow TORG on Twitter, Telegram, Facebook, and Medium.

Disclaimer: The information available on this article is for educational purposes only and not an offer, solicitation of an offer, or advice to buy or sell securities, investment or tax advice. Purchasing cryptocurrencies comes with a number of risks. All Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made here. The data and non-TORG names are for informational and identification purposes only.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jasper Lim
relations@thefms.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w

Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021

Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 20:46:00 CEST | Press release

Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli

Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 19:01:00 CEST | Press release

The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li

Wipro Announces Co-innovation Space with Google Cloud17.9.2021 15:32:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou

Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 15:00:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu

BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 14:00:00 CEST | Press release

BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.